Neuropathic pain is a debilitating form of chronic pain resulting from nerve injury, disease states, or toxic insults. Neuropathic pain is often refractory to conventional pharmacotherapies, necessitating validation of novel analgesics. Cannabinoids, drugs that share the same target as ⌬ 9 -tetrahydrocannabinol (⌬ 9 -THC), the psychoactive ingredient in cannabis, have the potential to address this unmet need. Here, we review studies evaluating cannabinoids for neuropathic pain management in the clinical and preclinical literature. Neuropathic pain associated with nerve injury, diabetes, chemotherapeutic treatment, human immunodeficiency virus, multiple sclerosis, and herpes zoster infection is considered. In animals, cannabinoids attenuate neuropathic nociception produced by traumatic nerve injury, disease, and toxic insults. Effects of mixed cannabinoid CB 1 /CB 2 agonists, CB 2 selective agonists, and modulators of the endocannabinoid system (i.e., inhibitors of transport or degradation) are compared. Effects of genetic disruption of cannabinoid receptors or enzymes controlling endocannabinoid degradation on neuropathic nociception are described. Specific forms of allodynia and hyperalgesia modulated by cannabinoids are also considered. In humans, effects of smoked marijuana, synthetic ⌬ 9 -THC analogs (e.g., Marinol, Cesamet) and medicinal cannabis preparations containing both ⌬ 9 -THC and cannabidiol (e.g., Sativex, Cannador) in neuropathic pain states are reviewed. Clinical studies largely affirm that neuropathic pain patients derive benefits from cannabinoid treatment. Subjective (i.e., rating scales) and objective (i.e., stimulusevoked) measures of pain and quality of life are considered. Finally, limitations of cannabinoid pharmacotherapies are discussed together with directions for future research.
physiological roles of cannabinoid receptors in the nervous system. Generation of CB 1 Ϫ/Ϫ mice that lack CB 1 receptors in nociceptive neurons in the peripheral nervous system while retaining CNS expression (SNS-CB 1 Ϫ ) has also documented a role for these receptors in controlling nociception. 7 CB 1 and CB 2 receptors exhibit disparate anatomical distributions.
3 CB 1 receptors are localized to the CNS and the periphery. CB 1 receptors are found in sites associated with pain processing, including the periaqueductal gray, 8 rostral ventromedial medulla, 8 thalamus, 9 dorsal root ganglia (DRG), 10 amygdala, 8 and cortex. 8 Densities of CB 1 receptors are low in brainstem sites critical for controlling heart rate and respiration. This distribution explains the low toxicity and absence of lethality after marijuana intoxication. Activation of the CB 1 receptor also results in hypothermia, sedation, catalepsy, and altered mental status. 11 Thus, it is critical for any cannabinoid-based pharmacotherapy targeting CB 1 receptors to balance clinically relevant therapeutic effects with unwanted side effects. The CB 2 receptor was originally believed to be restricted to the periphery, primarily to immune cells (e.g., mast cells). 12 They may be present neuronally in some species. The CB 2 receptor protein has been reported in the DRG, 13 brainstem, 14 thalamus, 15 periaqueductal gray, 15 and cerebellum 15, 16 of naive rats. CB 2 receptor levels in most CNS sites are present at only low levels under basal conditions (or are below the threshold for detection). However, an upregulation of CB 2 receptor immunoreactivity or mRNA is observed in sites implicated in nociceptive processing under conditions of induced neuropathy. 17 ,18 CB 2 receptors are localized to microglia, a resident population of macrophages within the CNS that are functionally and anatomically similar to mast cells. Microglia secrete proinflammatory factors and induce the release of several mediators (e.g., nitric oxide, neurotrophins, free radicals) that are associated with synaptogenesis and plasticity, leading to changes in neuronal excitability.
ENDOCANNABINOIDS
The first endogenous ligand for cannabinoid receptors 19 was named anandamide (AEA) after the sankrit word for bliss. Several other endocannabinoids including 2-arachydonoylglycerol (2-AG), 20, 21 noladin ether, 22 virodhamine, 23 and N-arachidonoly-dopamine 24 have been described. Fatty-acid amide hydrolase (FAAH) is the principle catabolic enzyme for fatty-acid amides including AEA and N-palmitoylethanolamine (PEA). 25 PEA does not bind cannabinoid receptors and has recently been described as an endogenous ligand for peroxisome proliferator receptor-␣ (PPAR-␣). 26 PEA may indirectly alter levels of endocannabinoids by competing with anandamide and other fatty-acid amides for degradation by FAAH or by suppressing FAAH expression at the transcriptional level. 27, 28 FAAH Ϫ/Ϫ mice are hypoalgesic in models of acute and inflammatory pain; these effects are blocked by a CB 1 antagonist. 29, 30 This basal hypoalgesia is absent in FAAH Ϫ/Ϫ mice subjected to nerve injury, where genotype differences in evoked neuropathic pain behaviors are not apparent. 30 Anandamide also acts as an endovanalloid at the transient receptor potential cation channel (TRPV1) receptor. 31 AEA shows affinity for TRPV1 that is 5-to 20-fold lower than its affinity for CB 1 . TRPV1 is not activated by classical, nonclassical, or aminoalkylindole cannabinoid agonists. AEA can also activate the peroxisome proliferator receptor-␥ (PPAR␥) receptor. 32 Thus, not all effects of AEA are mediated by cannabinoid receptors.
The metabolic pathways responsible for endocannabinoid degradation are well-characterized. Several FAAH inhibitors (e.g., OL135, URB597) have been developed and used to investigate physiological effects of increasing accumulation of AEA and other fatty-acid amides. Monoacylglycerol lipase (MGL) is a key enzyme implicated in the hydrolysis of 2-AG. 33 ,34 MGL inhibitors (e.g., URB602, JZL184) have been developed and can be used to selectively increase accumulation of this endocannabinoid. The endocannabinoid system has complex relationships with other metabolic pathways. Both AEA and 2-AG can be metabolized by cyclooxygenase-2, a phenomenon that may contribute to the antinociceptive properties of nonsteroidal antiinflammatory drugs that act through inhibition of cyclooxygenase-2.
4 Table 1 provides a summary of cannabinoids and related compounds that have been evaluated for efficacy in preclinical and clinical studies of neuropathic pain.
CANNABINOID MODULATION OF NEUROPATHIC NOCICEPTION IN ANIMAL MODELS
W. E. Dixon 35 was the first scientist to systematically study the antinociceptive properties of Cannabis sativa. Dixon 35 reported that cannabis smoke delivered to dogs attenuated their responsiveness to pin pricks. He observed that normally "evil-tempered and savage" dogs became "docile and affectionate" after exposure to cannabis, reflecting the psychotropic and mood-altering effects of cannabinoids. Motor effects observed after high doses of cannabinoids included drowsiness, awkward gate, and ataxia. Work by Walker's group subsequently demonstrated that cannabinoids suppress nociceptive transmission (for review see 36 ). Early observations of the antinociceptive properties of cannabinoids laid a foundation for future research examining the impact of canna-binoids and modulation of the endocannabinoid system on neuropathic pain.
Models of surgically-induced traumatic nerve injury
Cannabinoids suppress neuropathic nociception in at least nine different animal models of surgically-induced traumatic nerve or nervous system injury. Here, we review the literature with a focus on uncovering effects of different classes of cannabinoids on both neuropathic nociception and central sensitization in each model. We also consider the impact of nerve injury on the endocannabinoid signaling system. Where applicable, we review effects of neuropathic injury on levels of endocannabinoids and related lipid mediators, and we describe regulatory changes in CB 1 and CB 2 receptors induced by nerve injury. Finally, we will consider implications of the preclinical findings for cannabinoid-based pharmacotherapies for neuropathic pain in humans.
Chronic constriction injury
Chronic constriction injury (CCI) produces mechanical allodynia as well as thermal allodynia and hyperalgesia in the ipsilateral paw as early as 2 days postsurgery. 37 Initial reports failed to find mechanical hyperalgesia, although several of the reviewed articles report its presence after surgery. Very few studies have investigated the presence of cold allodynia after this nerve injury; however, those that have evaluated its presence uniformly demonstrate efficacy of cannabinoids in suppressing cold allodynia. CB 1 receptors are upregulated in the spinal cord after CCI; these effects are believed to be modulated by tyrosine kinase 38 and glucocorticoid 39 receptors. Not surprisingly, several classes of cannabinoids have been shown to suppress CCI-induced neuropathic nociception in rodents and include mixed cannabinoid agonists, which target both CB 1 and CB 2 receptors, CB 2 selective agonists, and modulators of the endocannabinoid system that inhibit FAAH or MGL (Tables 2 and 3) .
Chronic administration of synthetic analogues of natural cannabinoid ligands containing cannabidiol (CBD) attenuate or reverse established thermal and mechanical hyperalgesia in the CCI model. However, anti-hyperalgesic effects observed with these compounds are likely to be independent of cannabinoid receptors, and may be mediated through TRPV1. Those studies investigating pharmacological specificity have demonstrated blockade with the TRPV1 antagonist capsazepine, but not a cannabinoid CB 1 or CB 2 antagonist. 40, 41 The CB 1 specific antagonist SR141716 has been tested in this model with disparate results. SR141716, administered acutely, is pro-hyperalgesic and pro-allodynic in this model. 42 However, SR141716 (by mouth), administered chronically, suppresses thermal and mechanical hyperalgesia in both rats and CB 1 ϩ/ϩ mice, while failing to produce an effect in CB 1 Ϫ/Ϫ mice. 43 These reports are interspersed with a host of articles that indicate no antinociceptive or pro-nociceptive effects of either CB 1 or CB 2 antagonists, administered alone. Thus, it is important to emphasize that the behavioral phenotype induced by antagonist treatment may depend on the level of endocannabinoid tone present in the system, the injection paradigm (chronic 
FAAH ϭ fatty-acid amide hydrolase; MGL ϭ monoacylglycerol lipase; THC ϭ tetrahydrocannabinol.
vs acute), and the presence of regulatory changes in cannabinoid receptors or endocannabinoids.
Several mixed cannabinoid CB 1 /CB 2 agonists have been shown to suppress all forms of neuropathic nociception observed in the CCI model, primarily through CB 1 mediated mechanisms. Several studies, including the original study by Herzberg et al. 42 were conducted before the development of a CB 2 antagonist and recognition that CB 2 receptor mechanisms modulate neuropathic pain. 44 Mixed CB 1 /CB 2 agonists, such as CP55,940 or WIN55,212-2, typically act as CB 1 selective agonists after systemic administration, 45 although CB 2 mediated effects may be unmasked after administration of CB 2 selective agents or after local administration of the same compounds. A neurophysiological basis for these findings is derived from the observation that WIN55,212-2 (intravenously) dose dependently inhibits windup, 46 as well as CCI-induced increases in spontaneous firing 47 of spinal wide dynamic range (WDR) neurons through a CB 1 dependent mechanism. Spontaneous firing of WDR neurons is believed to contribute to behavioral hypersensitivity and neuronal sensitization in neuropathic pain states. WIN55,212-2 also normalizes prostaglandin E 2 levels and nitric oxide activity, two mediators of neuropathic pain that are increased after CCI. 48 Multiple CB 2 selective agonists have been demonstrated to suppress CCI-induced mechanical allodynia, although pharmacological specificity has not been consistently assessed (Table 2) . Thus, it is noteworthy that CB 2 receptor mRNA is upregulated in the lumbar spinal cord after CCI. This upregulation is restricted to nonneuronal cells (e.g., glia). 49 Interestingly, GW405833, a CB 2 specific agonist, also reduces depression-like behavior associated with this mononeuropathy in the forced swim test. 50 Tolerance, a feature that may contribute to loss of analgesic efficacy of currently available analgesics, failed to develop after repeated administration of the CB 2 specific agonist, A-836339. Thus, CB 2 agonists may show therapeutic potential for suppressing neuropathic pain without producing tolerance when administered either alone or as adjuncts to exisiting treatments. 51 Endocannabinoid modulators suppress neuropathic pain symptoms associated with CCI (Tables 2 and 3) . AM404, an endocannabinoid transport inhibitor, increases accumulation and, hence, bioavailability, of anandamide (and potentially other endocannabinoids) through a mechanism that remains incompletely understood. AM404 also normalizes CCI-induced changes innitric oxide activity, 52, 53 cyclooxygenase-2 53 activity, cytokine levels (e.g., tumor necrosis factor-␣ and interleukin-10), 52 and nuclear factor-B 52 levels. In CCI rats, chronic administration of either AM404 or URB597 suppresses plasma extravasation, a condition associated with neuropeptide release at peripheral levels. 54 ,55 AM404, administered chronically or acutely, does not affect locomotor behavior, indicating a low propensity of this agent to produce unwanted motor side effects associated with direct activation of CB 1 receptors. 52, 53 CCI produces regulatory changes in endocannabinoid levels. CCI increases AEA and 2-AG levels in the periaqueductal gray and rostral ventromedial medulla, sites implicated in the descending modulation of pain. 56 CCI also increases levels of endogenous AEA, but not 2-AG, in the dorsal raphe, which was an observation that may help explain the antihyperalgesic efficacy of an anandamide transport inhibitor in this model. 57 CCI increases serotonin (5-HT) levels in the dorsal raphe and this effect was suppressed by both WIN55,212-2 and AM404 in a CB 1 dependent manner. 57 CCI-induced Fos expression was observed in response to non-noxious mechanical stimulation in spinal cord laminae I and II, the site of termination of A␦ and C fibers, which carry nociceptive sensory information from the periphery to the CNS. Lower levels of evoked Fos expression were observed in laminae III and IV of CCI rats. Chronic administration of AM404 significantly decreased CCI-induced Fos expression in the lumbar spinal cord through CB 1 /CB 2 and TRPV1-mediated mechanisms. 58 Antinociceptive effects of FAAH inhibitors (OL135 and URB597) have also been reported in mice after CCI. OL135 and URB597 attenuate cold and mechanical allodynia in a manner that is dependent on activation of both CB 1 and CB 2 recep- tors. 59 In addition, both OL135 and URB597 are antinociceptive in FAAH ϩ/ϩ mice, but fail to produce an effect in FAAH Ϫ/Ϫ mice. 59 The novel MGL inhibitor, JZL184, attenuates CCI-induced mechanical and cold allodynia through indirect activation of the CB 1 receptor; JZL184 was efficacious in attenuating neuropathic nociception in both FAAH ϩ/ϩ and FAAH Ϫ/Ϫ mice. 59 The fatty acid PEA, administered chronically, attenuated the development of thermal hyperalgesia and mechanical allodynia in the CCI model through CB 1 , PPAR␥, and TRPV1-mediated mechanisms. 60 Chronic administration of PEA also normalized levels of three neutrophic factors (nerve growth factor, glial cell line-derived neurotrophic factor, and neurotrophin-3) that were increased by CCI. 60 Thus, activation of CB 1 and CB 2 receptors, as well as pharmacological manipulation of endocannabinoid accumulation or breakdown, suppresses neuropathic nociception in rodents.
Partial sciatic nerve ligation (Seltzer Model)
Mechanical hyperalgesia and allodynia are observed after partial ligation of the sciatic nerve. 61 Thermal hyperalgesia was present in all studies reviewed here that evaluated this measure with one exception. 62 Only two studies we reviewed examined the presence of cold allodynia after partial sciatic nerve ligation; the first study found that both CB 2 ϩ/ϩ and CB 2 Ϫ/Ϫ mice showed evidence of cold allodynia after surgery. 63 Cold allodynia has also been reported in rats after partial sciatic nerve ligation. 64 All classes of cannabinoids evaluated produced anti-allodynic and antihyperalgesic effects in the Seltzer model (Table 4) .
Pro-hyperalgesic effects of SR141716 and SR144528 have been reported in the Seltzer model, 65 indicating a potential alteration in endocannabinoid tone after nerve injury. No other articles we reviewed reported similar effects of cannabinoid antagonists administered alone in this model. Exogenously applied endocannabinoids, AEA and 2-AG, suppress changes in neuropathic nociception induced by partial sciatic nerve ligation. Interestingly, AEA produced anti-hyperalgesic and anti-allodynic effects through a CB 1 mechanism, 65,66 whereas 2-AG produced anti-hyperalgesic and anti-allodynic effects through activation of both peripheral CB 1 and CB 2 receptors. 67 AEA and PEA exerts effects, at least in part, through a peripheral mechanism; both fatty-acid amides suppressed release of calcitonin gene-related peptide and somatostatin evoked by the irritant resiniferotoxin without altering peptide release under basal conditions. 65 Antihyperalgesic effects of AEA and PEA were blocked by a CB 1 and CB 2 antagonist, respectively. 65 One limitation with studies using exogenous administration of endocannabinoids is that they do not imply that endocannabinoids are released under physiological conditions to produce these effects. Several studies report efficacy of mixed cannabinoid CB 1 /CB 2 agonists in this model, although CNS side effects were nonetheless observed in the same dose range that resulted in full reversal of neuropathic nociception. 68 Ajulemic acid (CT-3), which was developed as a peripherally restricted cannabinoid analogue, also produced activity in the tetrad, but antihyperalgesic effects occurred at doses lower than those producing side effects. 69 Structurally distinct CB 2 specific agonists are efficacious in suppressing neuropathic nociception in this model. Moreover, CB 2 receptors in the spinal cord contribute to CB 2 mediated suppression of mechanical allodynia. 70 CB 2 Ϫ/Ϫ mice reportedly develop thermal hyperalgesia and mechanical allodynia in the contralateral paw after surgery, whereas CB 2 ϩ/ϩ do not. 63 Microglia and astrocyte expression in the spinal dorsal horn is observed in both CB 2 Ϫ/Ϫ and CB 2 ϩ/ϩ mice ipsilateral to nerve injury. However, CB 2 Ϫ/Ϫ mice notably exhibit increased microglial and astrocyte expression in the contralateral spinal dorsal horn, a mechanism which may help to explain differences in neuropathic nociception between wild-types and knockouts. 63 Further support for this hypothesis is derived from the observation that overexpression of the CB 2 receptor attenuated enhanced expression of microglia. 63 These results suggest that genetic disruption of the CB 2 receptor has a disinhibitory effect on the responses of glial cells after partial sciatic nerve ligation. The cytokine, interferon-gamma, is produced by astrocytes and neurons ipsilateral to injury in both CB 2 ϩ/ϩ and CB 2 Ϫ/Ϫ mice. However, CB 2 Ϫ/Ϫ mice exposed to partial sciatic nerve ligation exhibit interferon-gamma immunoreactivity in the spinal dorsal horn contralateral to injury. Interferon-␥ Ϫ/Ϫ /CB 2 Ϫ/Ϫ mice showed no evidence of neuropathic nociception when the contralateral paw was stimulated after surgery, suggesting that immune responses underlie neuropathic pain responses observable in the contralateral paw of CB 2 Ϫ/Ϫ mice. 71 Deletion of a putative novel cannabinoid receptor, GPR55, is also associated with the failure to develop mechanical hyperalgesia after partial sciatic nerve ligation. 72 Compounds targeting three distinct mechanisms for modulating endocannabinoid levels also suppress neuropathic nociception after partial sciatic nerve ligation. The transport inhibitor AM404, administered systemically, suppressed mechanical allodynia in a CB 1 dependent manner without producing motor effects. 73 The FAAH inhibitor URB597, administered locally in the paw, 67 but not systemically, 62 suppressed both thermal hyperalgesia and mechanical allodynia through a CB 1 mechanism. The MGL inhibitor URB602 (which can not be used systemically as a selective MGL inhibitor), administered locally in the paw, also suppressed neuropathic nociception in this model through activation of both CB 1 and CB 2 receptors. 67 The fatty-acid analogue of PEA, L-29, also suppressed thermal hyperalgesia and mechanical al- 
AEA ϭ anandamide; 2-AG ϭ 2-arachydonoylglycerol; AJA ϭ ajulemic acid; i.p. ϭ intraperitoneal; i.pl. ϭ intraplantar; i.paw ϭ intra-paw; i.t. ϭ intrathecal; NaGly ϭ N-arachidonoyl glycine; NP ϭ not present; PEA ϭ palmitoylethanolamine; p.o. ϭ per orem; s.c. ϭ subcutaneous; SR1 ϭ SR141716; SR2 ϭ SR144528. White cells ϭ tested in rats. Shaded cells ϭ tested in mice. *Increased measurements in contralateral paw at dose(s) tested; † Chronic pre-emptive/postinjury or both; ‡ Postinjury; § Pre-emptive and postinjury combined; ¶ Only observed blockade for mechanical allodynia, not thermal hyperalgesia.
lodynia in the Seltzer model. The L29-induced suppression of thermal hyperalgesia was mediated by both the CB 1 receptor and PPAR-␣, whereas suppression of mechanical allodynia was mediated by CB 1 /CB 2 and PPAR-␣ receptors. 64 PEA abolished mechanical hyperalgesia after partial sciatic nerve ligation through a mechanism that was blocked by a CB 2 antagonist. 65 When considering the effects of PEA, it is important to emphasize that PEA does not bind directly to CB 2 receptors 74 ; therefore, blockade by a CB 2 specific antagonist could indicate indirect modulation of receptor activity (e.g., via activation of PPAR-␣ or entourage effects) or blockade of an uncharacterized cannabinoid receptor that binds the CB 2 antagonist SR144528. Intrathecal Narachidonoyl glycine (NaGly), the arachodonic acid conjugate, also attenuated mechanical allodynia in this model; however, the anti-hyperalgesic actions of this compound are independent of spinal cannabinoid receptors. 75 Locally injected (intra-paw) paracetamol suppressed mechanical allodynia and thermal hyperalgesia present after partial sciatic nerve ligation, and these effects were blocked by local administration of either a CB 1 or a CB 2 antagonist. 76 Paracetomol may undergo local metabolic transformation into AM404, resulting in increased levels of endocannabiniods.
Spinal nerve ligation (SNL)
All studies reviewed here documented the presence of mechanical allodynia after SNL. 77 All studies with the exception of one 78 indicated the presence of thermal hyperalgesia when animals were tested. One study evaluated the presence of cold allodynia and confirmed that animals with this injury display hypersensitivity to nonnoxious levels of cold stimulation. 79 Gabapentin successfully attenuated mechanical allodynia in this model, however, several other commonly prescribed neuropathic pain medications, including amitriptyline, fluoxetine, and indomethacin failed to show similar effects. 80 Thus, it is noteworthy that mixed cannabinoid agonists, cannabinoid CB 2 selective agonists, and FAAH inhibitors all attenuated neuropathic nociception induced by SNL ( Table 5) .
As with other nerve injury models, several mixed cannabinoid CB 1 /CB 2 agonists suppress hyperalgesia and allodynia produced by SNL. Acute WIN55,212-2 suppresses all forms of neuropathic nociception tested in this model. Chronic administration of WIN55,212-2 also attenuates the development of mechanical allodynia and suppresses glial activation in the spinal cord after SNL, with no overt motor side effects. 81 Chronic administration of WIN55,212-2 produced anti-allodynic effects for up to 6 days after the final injection. A reappearance of glial activation was also associated with return of neuropathic nociception in this study. 81 CP55,940 produces antinociception in CB 1 ϩ/ϩ , CB 2 ϩ/ϩ , CB 2 Ϫ/Ϫ , but not CB 1 Ϫ/Ϫ mice subjected to SNL, suggesting that activity at CB 1 dominates the antinocieptive profile of mixed CB 1 /CB 2 agonists after systemic administration. 45 Spinal, but not systemic, administration of HU-210 has been reported to reduce A␦ fiber-evoked responses on spinal WDR neurons in both shams and SNL rats, whereas HU-210 showed no effect on C-fiber responses of SNL rats. 82 SNL produces regulatory changes in CB 1 mRNA and endocannabinoid levels. Increases in CB 1 mRNA are observed in the uninjured (but abnormal) L4 DRG ipsilateral to injury. 83 Increases in both AEA and 2-AG have also been reported in the ipsilateral injured L5, but not the uninjured L4 DRG. 83 These findings collectively document the presence of regulatory changes in endocannabinoid levels associated with SNL, a finding which may contribute to the efficacy of peripherally administered cannabinoid agonists that activate CB 1 receptors in this model.
Noxious stimulation (e.g., C-fiber mediated activity) induces phosphorylation of extracellular signal-regulated protein kinase (ERK) in dorsal horn neurons. The CB 1 specific agonist ACEA inhibits pERK expression induced by in vitro application of capsaicin to the spinal cords of SNL rats. This observation contrasts with effects of opioids (i.e., morphine and DAMGO), which lose the ability to inhibit C-fiber induced ERK activation in the L5 spinal cord after SNL. 84 Multiple CB 2 specific agonists suppress neuropathic nociception induced by SNL. The CB 2 agonist AM1241 suppresses both thermal hyperalgesia and mechanical allodynia after SNL in both rats 17, 44, 85 and mice. 44 CB 1 Ϫ/Ϫ mice receiving AM1241 showed enhanced antihyperalgesia. 44 An emerging body of literature now suggests that antinociceptive effects of CB 2 agonists may be mediated by suppression of microglial activation. 4 Evidence for upregulation of CB 2 after SNL has been reported by several groups. CB 2 mRNA was upregulated in the lumbar spinal cord after SNL, 49 coincident with the expression of activated microglia. Colocalization studies, however, were not performed. Upregulation of CB 2 receptor immunoreactivity on sensory afferent terminals in the spinal cord has also been reported after SNL. 18 This group failed to find co-localization of CB 2 with markers for glial cells in SNL rats, and concluded that CB 2 receptors were upregulated on sensory neurons after spinal nerve ligation.
18 CB 2 mRNA was also shown to be upregulated in the ipsilateral (vs the contralateral) spinal cord and DRG after SNL, and the presence of CB 2 mRNA was confirmed in spinal cord microglial cells in culture. 17 The CB 2 specific agonist GW405833, administered chronically, suppressed the development of mechanical allodynia concomitant with suppression of glial activation at the level of the spinal cord. 81 The structurally distinct CB 2 specific agonist, JWH133, also attenuates mechanically-evoked responses of WDR neurons in both naive and spinal nerve ligated rats. 86 Local injection of JWH133 into the ventroposterolateral nucleus of the thalamus attenuated spontaneous and mechanicallyevoked neuronal activity in SNL, but not sham rats, in a CB 2 dependent manner. 87 Thus, CB 2 receptor activation may exert little functional control under nonpathological conditions. Systemic and spinal administration of the novel CB 2 agonist, A-836339, also attenuates spontaneous and mechanically-evoked neuronal firing of spinal WDR neurons in a CB 2 dependent manner in SNL, but not sham rats. 88 Interestingly, pretreatment with the CB 1 antagonist, SR141716, enhanced the effects of A-836339 when applied to the L5 DRG, 88 indicating that blockade of CB 1 receptors enhanced the antinociceptive effects of a CB 2 agonist, as previously reported. 89 Two endocannabinoid modulators have been evaluated behaviorally in this model. Compound 17, a novel FAAH inhibitor, reversed mechanical allodynia in SNL rats with the same potency as a 5-fold higher dose of gabapentin. 90 In addition, OL135, a compound that accesses the CNS and inhibits FAAH, suppressed mechanical allodynia in a CB 2 dependent manner. 91 Low doses of locally injected URB597 reduced mechanicallyevoked responses of WDR neurons and increased endocannabinoid levels in ipsilateral paw tissue of shamoperated rats.
92 A 4-fold higher dose was required for reduction of mechanically-evoked WDR neuronal responses in SNL rats; these rats showed no corresponding increase in endocannabinoid levels, suggesting that contributions of FAAH to endocannabinoid metabolism may be modified under conditions of neuropathic nociception. 92 The antinociceptive effects of URB597 were blocked by a CB 1 specific antagonist in both sham and SNL rats. 92 In the same study, spinal administration of URB597 was equally efficacious at attenuating mechanically-evoked responses and increasing levels of endogenous cannabinoids in SNL and sham rats, and these effects were CB 1 mediated.
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Other nerve injury models
Cannabinoids alleviate neuropathic nociception in several other injury models. These studies support a role for CB 1 in the anti-hyperalgesic effects of cannabinoids, although pharmacological specificity has not been consistently assessed in the literature and high doses of cannabinoid agonists can produce motor side effects, which complicate interpretation of behavioral studies. Chronic constriction injury of the infraorbital nerve results in thermal hyperalgesia and mechanical allodynia (as measured by head withdrawals) ipsilateral to the site of injury.
93 WIN55,212-2 and HU-210 increased mechanical withdrawal responses and thermal withdrawal latencies on the ipsilateral side of the head in this model.
94 WIN55,212-2 was more efficacious in suppressing mechanical allodynia versus thermal hyperalgesia in the chronic constriction injury of the infraorbital nerve model. High antihyperalgesic doses of WIN55,212-2 decreased rotarod latencies and body temperature, whereas HU210, at the singular low dose used (10 g/kg), had no effect on these dependent measures. CB 1 receptor upregulation was observed in both the ipsilateral and contralateral superficial layer of the trigeminal caudal nucleus, and this effect was greater on the ipsilateral side. These and earlier findings from the same group 95 indicate that cannabinoids are negative modulators of nociceptive transmission at the superficial layer of the trigeminal caudal subnucleus.
CB 2 receptor immunoreactivity 96 is increased in the ipsilateral dorsal horn after L5 spinal nerve transection. 97 Importantly, co-localization of CB 2 immunoreactivity with markers of microglia and perivascular cells was observed on day 4 postsurgery. 96 In this study, neither neuronal cells nor astrocyctes expressed immunoreactivity for CB 2 receptors.
96 CP55,940 reversed mechanical allodynia in this model 1 h after a second intrathecal injection, although this dosing paradigm was also associated with motor effects. 96 Intrathecal JWH015 dose dependently suppressed behavioral hypersensitivity after a second injection, indicating a cumulative anti-allodynic effect of this drug. Intrathecal JWH015 reduced spinal nerve transection-induced increases in activated microglia in a CB 2 dependent manner, further supporting a role for nonneuronal CB 2 receptors in antihyperalesic effects of CB 2 agonists. 96 Two models developed by Walczak et al. 98, 99 involved injuries to the saphenous nerve in rats and mice, respectively. The advantage of injuring the saphenous nerve in comparison with other nerves is that the saphenous nerve is an exclusively sensory nerve, whereas other nerve injury models typically target nerves that subserve both sensory and motor functions. The first model was produced in rats by saphenous partial nerve ligation, which involves trapping 30% to 50% of the saphenous nerve in a tight ligature. 98 Saphenous partial nerve ligation rats presented with all symptoms except mechanical hyperalgesia, which was present inconsistently throughout testing. WIN55,212-2, administered systemically, suppressed all forms of hyperalgesia and allodynia present. 98 In rats, saphenous partial nerve ligation increased -opioid, CB 1 , and CB 2 receptor protein in ipsilateral hind paw skin, DRG, and lumbar spinal cord. 98 In a second injury model, chronic constriction of the saphenous nerve was accomplished by tying two loose ligatures around the saphenous nerve in mice. 99 Systemic WIN55,212-2 suppressed all forms of neuropathic nociception present in this model, including thermal hyperagesia, cold allodynia, mechanical hyperalgesia, and mechanical allodynia. 99 Mu-opioid, CB 1 and CB 2 receptor protein was increased in the ipsilateral spinal cord and hind paw skin at 7 days postsurgery. 99 In addition, increased CB 1 receptor protein was observed in contralateral hind paw skin 7 days postsurgery and increased CB 2 receptor expression was observed in the contralateral spinal cord 1 and 7 days postsurgery. The neurobiological rearrangement of cannabinoid and mu-opioid receptors may contribute to the antinociceptive efficacy of WIN55,212-2 and morphine in this model.
The spared nerve injury (SNI) model reliably produces thermal hyperalgesia and mechanical allodynia in studies that tested for both measures. Initial reports of the SNI model indicated the presence of cold allodynia and mechanical hyperalgesia, 100 but none of the articles reviewed here assessed these behaviors in conjunction with cannabinoid treatment. Standard analgesics (e.g., morphine, gabapentin, amitryptiline) are efficacious in treating neuropathic nociception resulting from a crush injury of the sciatic nerve, but showed limited efficacy after SNI. 101 Two mixed cannabinoid CB 1 /CB 2 agonists have been tested in this model. Acute WIN55,212-2 suppressed thermal hyperalgesia and mechanical allodynia in both mice lacking CB 1 receptors in primary nociceptors (SNS-CB 1 Ϫ ) and their wild-type controls; however, differences in the antinociceptive effects of WIN55,212-2 were observed between genotypes, and these effects were greater with mechanical than thermal sensitivity. Comparable responses to WIN55,212-2 were only observed at doses high enough to induce sedation and rigidity in all mice. SNS-CB 1 Ϫ mice showed exaggerated sensitivity to noxious levels of mechanical stimulation and a cold plate relative to their wild-type counterparts, whereas differential sensitivity was not observed between genotypes with non-noxious levels of mechanical stimulation and noxious levels of thermal stimulation. 7 Thus, CB 1 receptors on nociceptors in the periphery account for much of the antinociceptive effects of cannabinoids. 7 A dose-escalation study with BAY 59-3074 in the SNI model indicated that tolerance rapidly develops to side effects observed after chronic administration (e.g., hypothermia), whereas no loss in analgesic efficacy was observed. 78 Spinal cord injury (SCI) 102 produces mechanical hyperalgesia and allodynia. WIN55,212-2 is the only compound that has been evaluated in the SCI model. Acute WIN55,212-2, administered systemically, suppressed SCI-induced mechanical allodynia in a CB 1 dependent manner, although other parameters of neuropathic pain were not assessed. 103 Unlike morphine, chronic administration of WIN55,212-2 reduced mechanical allodynia in the SCI model with no decrease in effectiveness over time. 104 Tibial nerve injury is performed by unilaterally axotomizing the tibial branch of the sciatic nerve. Mechanical allodynia and thermal hyperalgesia were present in the initial study describing this technique, 105 as well as the study we reviewed. Systemic BAY 59-3074 was shown to attenuate both forms of neuropathic nociception, although pharmacological specificity was not assessed. 78 Tibial nerve injury injury resulted in an upregulation of CB 1 receptor mRNA in the contralateral thalamus on day 1 postsurgery, 106 indicating cannabinoid receptor regulation within an important relay nucleus in the ascending pain pathway.
Disease-related models of neuropathic pain
Cannabinoid agonists have been evaluated in animal models of disease-related neuropathic pain, although pharmacological specificity has not been consistently assessed. Herein, we review effects of cannabinoids in preclinical models of neuropathic pain induced by diabetes, chemotherapeutic treatment, HIV/antiretroviral treatment, demyelination disorders, multiple sclerosis (MS), and postherpetic neuralgia.
Single injection of streptozotocin-induced diabetic neuropathy
Diabetic neuropathy induced by a single injection of streptozotocin (STZ) resulted in increased sensitivity to noxious and non-noxious levels of mechanical stimulation, and failed to induce thermal hyperalgesia in the studies reviewed here (Table 6) . None of the studies we reviewed evaluated the presence of cold allodynia. 2-Methyl-2'-F-anandamide (Met-F-AEA), a CB 1 specific agonist based on the structure of anandamide, the mixed cannabinoid agonist WIN55,212-2, and the CB 2 specific agonist AM1241, administered chronically, suppressed mechanical hyperalgesia associated with STZinduced diabetic neuropathy. However, mediation by cannabinoid receptors has not been assessed for agonists tested in this model. Daily pretreatment with indomethacin (cyclooxygenase-1 inhibitor) or L-NG-nitro arginine ([L-NOArg] nonselective nitric oxide synthase inhibitor) increased the antihyperalgesic actions of low doses of WIN55,212-2, AM1241, and Met-F-AEA in STZ rats to a greater extent than the cannabinoid administered alone, suggesting the presence of antinociceptive synergism between cannabinoid and cyclooxygenase pathways. 107 Cyclooxygenase inhibitors may block oxidative metabolism of endocannabinoids, thereby increasing endocannabinoids available to interact with cannabinoid receptors.
Diabetic rats exhibit a decrease in the density of CB 1 receptor protein in DRG. 108 More work is necessary to determine whether this loss of cannabinoid receptors contributes to the neurodegenerative process in diabetes. Increased levels of endocannabinoids have been found in obese patients suffering from type II diabetes, 109 and this effect is likely to result from downregulation of FAAH gene expression, an effect which has also been observed in adipocytes sampled from obese women. 110 Lean males subjected to hyperinsulinemia show a 2-fold increase in ddc ϭ zalcitabine; HIV-SN ϭ HIV sensory neuropathy (includes antiretroviral treatment (ddc), HIV-gp120, and HIV-gp120 ϩ antiretroviral treatment (ddc) models); i.t. ϭ intrathecal; i.p. ϭ intraperitoneal; i.pl. ϭ intraplantar; LDPN ϭ lysolecithin-induced demyelination-associated peripheral neuropathy of saphenous nerve; NP ϭ not present; SR1 ϭ SR141716; SR2 ϭ SR144528; VZV ϭ varicella zoster virus-induced neuropathy. White cells ϭ tested in rats. Shaded cells ϭ tested in mice. *Chronic postinjury; † Chronic, pre-emptive and postinjury; ‡ Increased measurements in contralateral paw at dose(s) tested; § In antiretroviral (ddc), HIV-gp120, and HIV-gp120 ϩ antiretroviral (ddc) models; ¶ Only tested in the antiretroviral (ddc) model. FAAH mRNA expression, whereas obese males subjected to the same conditions failed to show similar alterations in gene expression. 111 These findings are suggestive of a negative feedback mechanism that could result in downregulation of the endocannabinoid signaling system. The CB 1 antagonist rimonabant (Acomplia [Sanofi-Aventis, Montpellier, France]) ameliorates insulin resistance and decreases weight gain in patients suffering from metabolic syndromes. 112 In animal models, rimonabant improves resistance to insulin through pathways that are both dependent and independent of adiponectin, a hormone important for the regulation of glucose and catabolism of fatty acids. 113 Although adverse side effects have limited the potential therapeutic efficacy of Acomplia, drugs modulating the endocannabinoid system should not be disregarded as targets for potential treatments of diabetes and its associated syndromes. STZ-diabetic mice showed a progressive decline in the radial arm maze and reduced neurological scores, both of which were recovered after treatment with HU-210. 114 However, these effects were not blocked by a CB 1 specific agonist. HU-210 did not alter the hyperglycemia index; however, it did normalize cerebral oxidative stress present in diabetic mice. 114 An increase in the number of apoptotic cells and impaired neurite growth was observed in PC12 cells cultured under hyperglycemic conditions, and these were effectively treated by HU-210. 114 Cannabinoids may show greater therapeutic potential for treating painful diabetic neuropathy compared to opioids. Interestingly, ⌬ 9 -THC exhibited enhanced antinociceptive efficacy in diabetic rats, whereas morphine showed reduced antinociceptive efficacy. 115 Moreover, a non-nociceptive dose of ⌬ 9 -THC, administered in conjunction with morphine, enhanced the antinociceptive properties of morphine in both diabetic and naive mice. 115 Thus, combinations of opioids and cannabinoids may show promise as adjunctive analgesics in humans. Diabetic rats exhibit lower levels of dynorphin and ␤-endorphins in CSF relative to nondiabetic rats treated under the same conditions. 115 Administration of ⌬ 9 -THC to diabetic rats restored CSF levels of endogenous dynorphin and leu-enkephalin to levels observed after morphine administration to nondiabetic rats. 115 More work is necessary to understand the mechanism underlying these observations.
Chemotherapy-induced neuropathy
Cannabinoid modulation of chemotherapy-induced neuropathy has been evaluated with agents from three major classes of chemotherapeutic agents (Table 6) . A singular study has evaluated cannabinoid modulation of neuropathic nociception induced by cisplatin, a platinum-derived agent. WIN55,212-2 prevented the development of mechanical allodynia induced by cisplatin, but failed to produce an anti-emetic benefit in this study. 116 It is possible that the dose of cannabinoid employed, the species used (rat) or toxicity of cisplatin-dosing paradigms may prevent detection of anti-emetic effects in this model. Cannabinoids have been shown to suppress cisplatin-induced emesis in the least shrew. 117 Paclitaxel has been most frequently studied in the cannabinoid literature with three studies documenting cannabinoid-mediated suppression of paclitaxel-induced neuropathic nociception. In one study, paclitaxel 118 produced mechanical allodynia starting on day 5 that continued throughout the course of study, although thermal hyperalgesia was only present from days 18 to 21.
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WIN55,212-2 suppressed neuropathic nociception in this model, but had no effect on body temperature or immobility. WIN55,212-2-induced decreases in spontaneous motor activity were nonetheless observed. 119 A more recent study using the same paclitaxel dosing paradigm 118 reported the presence of mechanical allodynia and the absence of thermal hyperalgesia. 85 Naguib et al. 85 demonstrated that a novel CB 2 specific agonist, MDA7, suppressed paclitaxel-induced mechanical allodynia, although mediation by CB 2 receptors was not assessed. Using the paclitaxel dosing paradigm described by Flatters and Bennett, 120 mechanical allodynia, but not thermal hyperalgesia, was observed. In this model, rats showed signs of mechanical allodynia up to 72 days post-paclitaxel. 89 Systemic administration of either the CB 2 agonist (R,S)-AM1241 or its receptor-active enantiomer (R)-AM1241 produced CB 2 mediated suppressions of paclitaxel-induced mechanical allodynia. (S)-AM1241, the enantiomer exhibiting lower affinity for the CB 2 receptor, failed to produce an anti-allodynic effect. 89 The novel cannabilactone, AM1714, also reversed mechanical allodynia associated with paclitaxel treatment in a CB 2 dependent manner. 89 Thus, both mixed CB 1 /CB 2 agonists and selective CB 2 agonists suppress paclitaxel-evoked mechanical allodynia.
Cannabinoid modulation of neuropathic nociception has also been evaluated with vincristine, an agent from the vinca-alkaloid class of chemotherapeutic agents. Vincristine produced mechanical allodynia, but not thermal hyperalgesia, in a 10-day injection paradigm. 121 Systemic and intrathecal, but not intraplantar, WIN55,212-2 suppressed vincristine-induced mechanical allodynia through activation of CB 1 and CB 2 receptors. 122 These findings implicate the spinal cord as an important site of action mediating anti-allodynic effects of cannabinoids. Systemic (R,S)-AM1241 also partially reversed vincristine-induced mechanical allodynia in a CB 2 dependent manner. 122 The anti-allodynic effects of WIN55,212-2 and (R,S)-AM1241 were observed at doses that did not produce intrinsic effects on motor behavior in the bar test. 122 Our studies suggest that clinical trials of canna-binoids for the management of chemotherapy-evoked neuropathy are warranted.
HIV-associated sensory neuropathy
The mixed cannabinoid agonist WIN55,212-2 is an effective anti-hyperalgesic agent in three distinct animal models of HIV-associated sensory neuropathy (Table 6 ). Rats treated with the antiretroviral agent zalcitabine (ddc) developed mechanical allodynia that persisted up to 43 days postinjection and peaked between days 14 and 32. 123 No hypersensitivity to thermal stimuli or motor deficits was observed after ddc treatment. HIV-1 has indirect interactions with neurons through its binding affinity to the external envelope binding protein gp120; researchers have exploited this mechanism to demonstrate development of peripheral neuropathy in rodents after exposure of the sciatic nerve to the HIV-1 gp120 protein. Perineural HIV-gp120 together with ddc treatment resulted in mechanical allodynia that was greater than either treatment alone; no changes in paw withdrawal latencies to thermal stimuli or motor deficits were reported. 123 Thigmotaxis was present in animals receiving ddc, either alone or in conjunction with HIV-gp120, indicating the presence of anxiety-like behavior in these rats. 123 Rats receiving ddc displayed modest levels of gliosis, whereas combined treatment with both HIV-gp120 and ddc increased levels of microglial activation. 123 Importantly, chronic WIN55,212-2 reversed mechanical allodynia induced by either ddc treatment 123 or HIV-gp120 exposure, 124 whereas animals subjected to both HIV-gp120 and ddc treatment exhibited a WIN55,212-2-induced attenuation of mechanical allodynia. 123 Increases in the density of microglia and astrocytes were observed in the ipsilateral dorsal horn after HIV-gp120 treatment. Thus, activated microglia may be a common target underlying cannabinoid-mediated suppressions of neuropathic nociception.
Demyelination-induced neuropathy
WIN55,212-2 has been evaluated in the lysolecithin-induced demyelination model (Table 6 ). Heightened sensitivity to both non-noxious and noxious mechanical stimulation is observed in lysolecithin-treated rats; this hypersensitivity emerged 5 days postexposure and peaked between 9 and 15 days postexposure. 125 Recovery to baseline levels was observed by day 23 post-lysolecithin. WIN55,212-2 attenuated mechanical allodynia and thermal hyperalgesia in this model and remained efficacious for up to 1 hour postinjection. 125 By contrast, DAMGO failed to produce an effect. Notably, the antihyperalgesic and anti-allodynic effects of WIN55,212-2 were reversed by a CB 1 specific antagonist in both tests.
MS-associated neuropathy
Animal models of MS have been described, although to our knowledge, no study to date has evaluated cannabinoid-mediated suppression of MS-induced neuropathic nociception. Lynch et al. 126 reported the presence of thermal hyperalgesia (tail immersion) and mechanical allodynia in mice that were infected with Theiler's murine encephalomyelitis virus. Interestingly, female mice showed an increased rate of development and greater allodynia than their male counterparts, a finding which mimics the greater prevalence of neuropathic pain symptoms reported by female MS patients. 127 Cold and mechanical allodynia, but not thermal hyperalgesia, have been reported in a model of autoimmune encephalomyelitis in which mice were immunized with myelin oligodendrocyte glycoprotein (MOG ) 128 ; autoimmune encephalomyelitis has been postulated to underlie the development of neuropathic pain in MS. Interestingly, a mouse model of MS (Theiler's murine encephalomyelitis virus infection) is also characterized by an upregulation of CB 2 receptor mRNA and increases in levels of 2-AG and PEA. 129 Animals treated subchronically with PEA showed improvements in tests of motor performance, measures that were impaired after Theiler's murine encephalomyelitis virus infection. 129 Thus, we postulate that cannabinoid CB 2 agonists and modulators of endogenous cannabinoids (e.g., MGL inhibitors) would exhibit anti-allodynic efficacy in this model.
Postherpetic neuralgia
Cannabinoids and fatty-acid amides suppress neuropathic nociception in an animal model of postherpetic neuralgia (Table 6 ). However, pharmacological specificity has not been consistently assessed in this model. Approximately 50% of rats exposed to the varicellazoster virus developed mechanical allodynia in the ipsilateral paw by 14 days postinfection; no thermal hyperalgesia or cold allodynia was observed. 64 The PEA analogue L-29 suppressed mechanical allodynia in this model with an earlier onset relative to gabapentin. However, neither a CB 1 nor CB 2 specific antagonist blocked L-29 mediated suppression of varicella-zoster virus-induced mechanical allodynia. 64 This finding is perhaps unsurprising given that PPAR-␣ mediates effects of PEA in suppressing neuronal sensitization. 130 However, L-29, nonetheless, suppressed neuropathic nociception in the Seltzer model via activation of CB 1 and CB 2 receptors (see Table 4 ). Systemic WIN55,212-2, administered from days 18 to 21 postinfection, fully reversed mechanical allodynia to baseline levels in this model of postherpetic neuralgia, although pharmacological specificity was not assessed.
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CANNABINOID MODULATION OF NEUROPATHIC PAIN IN CLINICAL STUDIES
Cannabinoids have been evaluated in clinical studies for their suppression of acute, postoperative and neuro-pathic pain. Based on our reviews of the literature, cannabinoids exhibit their greatest efficacy when used for the management of neuropathic pain (Tables 7 and 8) . 132 There are approximately 460 known chemical constituents in cannabis. Thus, at the outset, it is important to emphasize that smoked cannabis is not the same as oral ⌬ 9 -THC or different mixtures of ⌬ 9 -THC and CBD (e.g., Sativex [GW Pharmaceuticals, United Kingdom] and Cannador [Institute for Clinical Research, IKF, Berlin, Germany]). Other drug delivery mechanisms (e.g., oralmucosal sprays and rectal suppositories containing cannabinoids) have been developed. Evidence to date from clinical studies suggests that these compounds show therapeutic efficacy in suppressing neuropathic pain (Table 7 and 8).
Three of the articles reviewed here used smoking as the route of administration, whereas the other 13 used oral preparations in the form of pills or oral-mucosal sprays. Side effects were reported in all studies in a proportion of patients receiving cannabinoid-based medications. The most frequently reported side effects were dizziness, impairment of balance, feelings of intoxication, dry mouth, and dysgeusia (most commonly observed with oral-mucosal sprays), sedation, and hunger. One study reported severe gastrointestinal effects for 10% of patients taking Sativex versus 0% reporting similar problems in the placebo group. 133 However, unwanted side effects, in contrast to analgesic effects, may undergo tolerance. 134 Side effects may be minimized using dosing paradigms employing low doses that are only gradually escalated. As follows, we review effects of cannabinoid-based medications in clinical studies using populations of patients presenting with neuropathic pain. Neuropathic pain induced by HIV infection and/or antiretroviral treatment, MS, brachial plexus avulsion, mixed treatment-resistant neuropathic pain, and others were considered.
HIV-associated neuropathy
Two studies have examined effects of smoked cannabis for the treatment of HIV-associated sensory neuropathy (resulting from HIV infection, dideoxynucleoside antiretroviral therapy, or both) and have reported positive results (Table 7) . Abrams et al. 135 reported that 52% of patients (i.e., 13 of 25 receiving cannabis cigarettes) experienced a greater than 30% reduction in pain (visual analogue scale daily ratings [VAS]). Stimulus-evoked pain testing revealed that the group receiving cannabis experienced a reduction in the area sensitive to mechanical allodynia (with a foam brush or 26 g von Frey hair) in the heat and capsaicin sensitization model. Moreover, CD4ϩ, CD8ϩ, and T-cell counts were not negatively impacted by cannabinoid treatment in HIV patients. 136 In 2009, Ellis et al. 137 reported similar results in a crossover study using multiple concentrations of ⌬ 9 -THC in cannabis cigarettes administered to patients. Cannabis was superior to a placebo in either phase of the crossover, as measured with the descriptor differential scale or VAS. This study found no changes in heart rate, blood pressure, plasma HIV RNA (viral load; VL), or blood CD4ϩ lymphocyte counts after cannabis treatment, suggesting that cannabis did not negatively impact the already compromised immune system in these patients. An anonymous cross-sectional questionnaire study revealed that as many as one third of patients suffering from HIV have used cannabis to treat symptoms. 138 Patients reported self-dosing with marijuana primarily between 6 PM and 12 AM. Among the symptoms improved after cannabis were appetite (97% reported improvement), pain (improved in 94% of the patients with pain), nausea (93% reported improvement), and anxiety (93% reported improvement). 138 Dronabinol (Marinol [Solvay Pharmaceuticals Inc, Marietta, GA]) is used to counteract AIDS-related wasting and promote appetite in patients suffering from AIDS-related anorexia. 139 The benefits of ⌬ 9 -THC and Nabilone (Cesamet [Valeant Pharmaceuticals International, Aliso Viejo, CA]) for the treatment of chemotherapy-induced nausea and vomiting have also been validated. 140, 141 Thus, several features of cannabinoid pharmacology are particularly desirable for an analgesic intervention aimed at managing neuropathic pain in AIDS and cancer patients.
MS-induced neuropathic pain
Several cannabinoid-based medicines have been evaluated in patients suffering from MS-related neuropathic pain. Cannabinoid-based medications have more frequently been evaluated for efficacy in suppressing MSrelated spasticity. 142 Dronabinol reduced spontaneous pain intensity as measured with a numerical rating scale (NRS) for a 3-week treatment period, 134 and improved overall pain ratings on the category rating scale for a 15-week treatment period. 143 In addition, this drug improved median radiating pain intensity and pressure threshold, 134 sleep quality, spasms, and spasticity 143 in MS patients. Cannador is a medicinal cannabis preparation containing ⌬ 9 -THC and CBD in a 2:1 ratio. CBD is a natural constituent in cannabis, which has very low affinity for cannabinoid CB 1 and CB 2 receptors. It may act as a high potency antagonist of cannabinoid agonists and an inverse agonist at CB 2 receptors. 144 CBD may compete with cannabinoid agonists for cannabinoid receptor binding sites, thereby minimizing psychoactivity of drugs that use a combination of ⌬ 9 -THC and CBD. The antinociceptive effects of CBD have also been attributed to inhibition of anandamide degradation, the antioxidant properties of the compound, or binding to an unknown cannabinoid receptor. 144 CBD also acts as an agonist at serotonin 5-HT1a receptors. 144 Cannador, ad- (Table continues) ministered for a 15-week treatment period, improved overall pain ratings, as well as sleep quality, spasms, and spasticity on category rating scales in patients suffering from MS-related neuropathic pain. 143 A 1-year, doubleblind, placebo-controlled follow-up study in MS patients demonstrated improved symptoms of pain, spasms, spasticity, sleep, shakiness, energy level, and tiredness after administration of either dronabinol or Cannador. 145 This study reported that 74% of the patients in the placebo group, versus 45% of the patients receiving cannabinoidbased medications, cited a lack of benefit derived from experimental medication as the reason for discontinuation of the trial. 145 MS patients receiving Sativex (a medicinal cannabis extract containing approximately a 1:1 ratio of CBD:⌬ 9 -THC, administered as an oral-mucosal spray) reported significant reductions in pain symptoms, as measured with the NRS-11 and neuropathic pain scale in a 4-week treatment period, double-blind, placebocontrolled study. 146 Ninety-five percent of the patients in the placebo-controlled study chose to enter a 2-year open-label study with Sativex. 147 Fifty-four percent of the patients completed 1 year and 44% of the patients completed 2 years of the study. Twenty-five percent withdrew due to adverse events, and 95% experienced one or more adverse events during the course of treatment. The NRS-11, completed at the end of the trial, or upon withdrawal, was not different from the earlier randomized study indicating that Sativex was still suppressing pain. In addition, patients did not increase the titration of their dose indicating that no tolerance developed to Sativex. Most doses of Sativex were administered between 6 PM and 12 AM, demonstrating that pain symptoms may be at their worst during normal sleeping hours for MS patients. A recent meta-analysis examining six studies of cannabinoid-based medications used for the treatment of MS-related neuropathic pain revealed that cannabis preparations were superior to a placebo. 148 Increased CB 2 immunoreactivity has been reported in spinal cords derived from MS patients. 149 Here, greater numbers of microglia/macrophage cells expressing CB 2 immunoreactivity were observed relative to controls. 149 Thus, cannabinoid-based pharmacotherapies consistently show efficacy for suppressing pain due to MS, a disease state associated with an upregulation of CB 2 receptors in microglia.
Brachial plexus avulsion-induced neuropathy
A single study has examined patients with neuropathic pain resulting exclusively from a brachial plexus avulsion (Table 8 ). This study 150 used a 3-period crossover design with patients self-administering ⌬ 9 -THC, Sativex, or a placebo for 14 to 20 days per drug. Both ⌬ 9 -THC and Sativex reduced the primary outcome measure (boxscale 11 ordinal rating scale) in patients suffering from brachial plexus avulsion, indicating a reduction in pain 151 However, upregulation of CB 2 receptor immunoreactivity was specifically observed in injured human nerve specimens and avulsed DRG obtained during surgery for brachial plexus repair. 151 These observations correspond to preclinical observations of cannabinoid receptor upregulation after nerve injury. 18 However, possible changes in CB 1 receptor immunoreactivity were not evaluated in the human tissue, and therefore can not be excluded.
Mixed neuropathic pain
Recruitment of a patient population suffering from a specific form of neuropathic pain can be a difficult prospect; therefore, several studies include patients in which neuropathic pain is associated with different disease states or injuries (Table 8) . A 21-patient study reported that ajulemic acid (CT-3) suppressed mixed forms of neuropathic pain, as assessed with the VAS, in the morning (3 h after drug administration), but not in the afternoon (8 h after drug administration). 152 Eighteen of those same patients participated in stimulus-evoked pain testing during the study, and those patients showed a trend toward decreased mechanical allodynia after CT-3 administration. 153 CT-3 binds with high affinity to both CB 1 and CB 2 receptors, and also binds with low affinity to PPAR␥ receptors. 154 CT-3 has limited CNS availability, 69 which translates into fewer CB 1 -mediated sideeffects.
Smoking cannabis cigarettes also improved spontaneous pain relief and pain unpleasantness VAS ratings in patients suffering from mixed forms of neuropathic pain, but failed to alter stimulus-evoked pain. 155 This study reported that cannabinoids compounded the decreased neurocognitive performance of patients that was present at baseline. Using an "N of 1" preparation, Notcutt et al. 156 determined if patients experienced improvements in pain after a 2-week open-label phase with Sativex prior to initiation of the double-blind, placebo-controlled crossover phase of the study. ⌬ 9 -THC and Sativex, but not placebo or CBD, reduced the VAS rating of the two worst pain symptoms during the crossover phase. 156 Quality of sleep was improved by all cannabinoid-based medications 156 and therefore may contribute to the therapeutic potential of the cannabinoids. By contrast, opioid analgesics produce deleterious effects on sleep architecture, including reductions in slow wave sleep and promotion of sleep apnea. 157, 158 A similarly structured study reported improved pain ratings (VAS) and spasticity severity after CBD and ⌬ 9 -THC in patients with mixed neuropathic pain.
159 ⌬ 9 -THC and Sativex also improved muscle spasms and spasticity severity. 159 Sativex improved pain ratings as measured with the NRS in a 5-week, double-blind, placebo-controlled study performed in patients experiencing unilateral neuropathic pain. 133 In this study, Sativex reduced mechanical dynamic and punctate allodynia, and improved sleep disturbances. 133 Seventy-one percent of the patients tested chose to continue to the open-label study of Sativex with 63% withdrawing by the end of the study for various reasons. Nabilone (Cesamet) decreased measures of spasticity-related pain (11-point box test) in patients experiencing chronic upper motor neuron syndrome associated with a number of pain syndromes. 160 In a retrospective review of patient charts at the Pain Center of the McGill University Health Center from 1999 to 2003, 161 75% of patients received some benefit from taking Nabilone (whether it came in the form of pain relief, improved sleep, decreased nausea, or increased appetite).
Two studies have examined the effects of cannabinoidbased medications in patients suffering from spinal cord injuries. An early case study reported pain relief and improvement in spasticity in a patient with a spinal cord injury after oral ⌬ 9 -THC. 162 A later study reported that 18% of the patients with spinal cord injuries reported pain relief after treatment with oral dronabinol (mean, 31 mg per day), whereas 23% experienced enhancement of pain resulting in subsequent withdrawal by several patients. 163 Changes in experimental design after initiation of the study complicate interpretation of these latter findings. 163 
Caveats
We are aware of only two clinical studies that have failed to report efficacy of cannabinoids, relative to placebo, for treatment of mixed neuropathic pain. 164, 165 Our analysis of the study by Clermont-Gnamien et al. 165 is restricted to information provided in the abstract, published in English. Both of these studies used eight or fewer subjects and evaluated dronabinol titrated to a dose of 25 mg/day (where tolerated). The mean dose was 16.6 Ϯ 6.5 mg oral dronabinol in one study 164 and 15 Ϯ 6 mg in the other study. 165 The two studies associated with negative outcomes for cannabinoids in managing neuropathic pain shared several common features: 1) evaluation of mixed neuropathic pain syndromes known to be refractory to multiple analgesic treatments, 2) evaluation of orally-administered ⌬ 9 -THC (dronabinol) as opposed to mixtures of ⌬ 9 -THC and CBD, or smoked marijuana, 3) small numbers of subjects, and 4) observation of prominent side effects (e.g., sedation) resulting in high dropout rates. One study reported side effects that were more prominent in older patients and did not cor-relate with analgesia. 164 Of course, one difficulty in evaluating efficacy of analgesics in patients with neuropathic pain refractory to all known treatments is that there is no indication that these patients would respond favorably to any analgesic under the study conditions. In a third study, effects of Nabilone were compared with dihydrocodeine in a randomized, crossover, double-blind study of 3-months duration that did not include a pharmacologically inert placebo condition. In this latter study, 166 it was concluded that the weak opioid dihydrocodeine was a statistically better treatment for chronic neuropathic pain than Nabilone. 166 Patients in this study exhibited a mean baseline VAS rating of 69.6 mm on a 0 to 100 mm VAS scale; mean VAS ratings were 59.93 Ϯ 24.42 mm and 58.58 Ϯ 24.08 mm for patients taking Nabilone and dihydrocodeine, respectively. However, the authors noted that a small number of subjects responded well to Nabilone, and side effects were generally mild and in the expected range. 166 Benefits of an add-on treatment with Nabilone have nonetheless been noted in patients with chronic therapy-resistant pain (observed in a causal relationship with a pathological status of the skeletal and locomotor system). 167 Oral dronabinol produced significant pain relief versus placebo when combined with opioid therapy in both a double-blind, placebo-controlled crossover phase and a subsequent open-label extension. 168 Patients also reported improvements in sleep problems and disturbances while experiencing an increase in sleep adequacy in the open-label phase of the study. 168 Thus, caution should be exerted prior to concluding that side effects of cannabinoids seriously limit the therapeutic potential of cannabinoid pharmacotherapies for pain. Combination therapies, including a cannabinoid and opioid analgesic, show efficacy for treatmentresistant neuropathic pain and may be used to limit doses of analgesics or adjuvants associated with adverse side effects.
Side effects
Diverse neuropathic pain states (characterized as idiopathic, diabetic, immune-mediated, cobalamin-deficiency related, monoclonal gammopathy-related, alcohol abuse-related, and other) were recently examined in a prospective evaluation of specific chronic polyneuropathy syndromes and their response to pharmacological therapies. 169 Intolerable side effects were observed in all groups of patients receiving either gabapentainoids, tricyclic antidepressants, anticonvulsants, cannabinoids (Nabilone or Sativex), or topical agents. 169 Notably, the presence of intolerable side effects was similar among the different classes of medications. 169 In this study, most forms of neuropathic pain had similar prevalence rates and responsiveness to the different pharmacotherapies evaluated. 169 A recent systematic review of adverse effects of medical cannabinoids concluded that most adverse events (96.6%) were not serious and no serious adverse events were related exclusively to cannabinoid administration. Moreover, 99% of serious adverse events from randomized clinical trials were reported in only two trials. 170 Greater numbers of nonserious adverse events were observed after cannabinoid treatment, as expected. 170 Side effects were equally associated with the different cannabinoid pharmacotherapies; the average rate of nonserious adverse events was higher in patients receiving Sativex or oral ⌬ 9 -THC than controls. 170 Thus, the main burden for the clinician is to balance therapeutic efficacy with the risk of intolerable side effects in the specific patient. 169 High-quality trials of long-term exposure to cannabinoids-based medications, together with careful monitoring of patients, are required to better characterize safety issues related to the use of medical cannabinoids. 170 
CONCLUSIONS
Cannabis has been used for pain relief for centuries, although the mechanism underlying their analgesic effects was poorly understood until the discovery of cannabinoid receptors, and their endogenous ligands in the 1990s. During the last two decades, a large number of research articles have demonstrated the efficacy of cannabinoids and modulators of the endocannabinoid system in suppressing neuropathic pain in animal models. Cannabinoids suppress hyperalgesia and allodynia (i.e., mechanical allodynia, mechanical hyperalgesia, thermal hyperalgesia, and cold allodynia where evaluated), induced by diverse neuropathic pain states through CB 1 and CB 2 specific mechanisms. These studies have elucidated neuronal as well as nonneuronal sites (i.e., activated microglia) of action for cannabinoids in suppressing pathological pain states and documented regulatory changes in cannabinoid receptors and endocannabinoid accumulation in response to peripheral or central nervous system injury. Clinical studies largely reaffirm that cannabinoids show efficacy in suppressing diverse neuropathic pain states in humans. The psychoactive effects of centrally-acting cannabinoid agonists, nonetheless, represent a challenge for pain pharmacotherapies that directly activate CB 1 receptors in the brain. However, nonserious adverse events (e.g., dizziness), which pose the major limitation to patient compliance with pharmacotherapy, are not unique to cannabinoids. Approaches that serve to minimize unwanted CNS side effects (e.g., by combining ⌬ 9 -THC with CBD, or by targeting CB 2 receptors, peripheral CB 1 receptors, or the endocannabinoid system) represent an important direction for future research and clinical evaluation. The present review suggests that cannabinoids show promise for treatment of neuropathic pain in humans either alone or as an add-on to other therapeutic agents. Therefore, further evaluations of safety profiles associated with long-term effects of cannabinoids are warranted.
